- Home
- / Qiagen
Qiagen
Stock Price
€36
2023-11-14
Market Capitalization
€8.3 B
2023-11-14
Revenue
$2.1 B
FY, 2022
Qiagen Summary
Company Summary
- Overview
- Qiagen is a company that provides sample and assay technologies for molecular testing. It offers automated sample preparation, liquid biopsy, cancer research, syndromic testing, enzymes exploration, viral load detection and monitoring. The company serves molecular diagnostics, life sciences, pharmaceutical, applied testing, and other sectors.
- Type
- Public
- Status
- Active
- Founded
- 1984
- HQ
- Tegelen, NL | view all locations
- Website
- https://www.qiagen.com/us
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Stephany Foster Spahr, Senior Vice President, Head of Human Resources
Jonathan Sheldon, Senior Vice President, QIAGEN Digital Insights Business Area
Roland Sackers, Chief Financial Officer and Managing Director
Operating MetricsView all
Customers
500K
FY, 2022
Products
500
FY, 2021
Institutional Investors
500K
83233.3%
FY, 2022
LocationsView all
49 locations detected
Tegelen, LI HQ
Netherlands
Hulsterweg 82
Ann Arbor, MI
United States
1250 Eisenhower Pl
Beverly, MA
United States
100 Cummings Center #407J
Germantown, MD
United States
19300 Germantown Rd
Redwood City, CA
United States
1001 Marshall St #200
Clayton, VIC
Australia
1894 Dandenong Rd
Qiagen Financials
Summary Financials
- Revenue (Q2, 2023)
- $494.9M
- Gross profit (Q2, 2023)
- $304.9M
- Net income (Q2, 2023)
- $80.8M
- Cash (Q2, 2023)
- $609.5M
- EBIT (Q2, 2023)
- $94.5M
- Enterprise value
- $9.5B